161 related articles for article (PubMed ID: 38443220)
41. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
42. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
Al-Juhaishi T; Ahmed S
Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
[TBL] [Abstract][Full Text] [Related]
43. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
Perica K; Curran KJ; Brentjens RJ; Giralt SA
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1135-1141. PubMed ID: 29499327
[TBL] [Abstract][Full Text] [Related]
44. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
[TBL] [Abstract][Full Text] [Related]
45. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
Kiani J; Naderi M; Torabi-Rahvar M; Ranjbar A; Aghayan HR; Janzamin E; Ahmadbeigi N
Arch Iran Med; 2019 Jan; 22(1):7-10. PubMed ID: 30821155
[TBL] [Abstract][Full Text] [Related]
46. Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities.
Weinkove R; George P; Ruka M; Haira TH; Giunti G
N Z Med J; 2021 Sep; 134(1542):96-108. PubMed ID: 34531588
[TBL] [Abstract][Full Text] [Related]
47. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
Halford Z; Anderson MK; Bennett LL; Moody J
Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
[TBL] [Abstract][Full Text] [Related]
48. [Immunotherapy with CAR-T cells in paediatric haematology-oncology].
Mirones I; Moreno L; Patiño-García A; Lizeaga G; Moraleda JM; Toribio ML; Pérez-Martínez A; ;
An Pediatr (Engl Ed); 2020 Jul; 93(1):59.e1-59.e10. PubMed ID: 32107177
[TBL] [Abstract][Full Text] [Related]
49. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Ghilardi G; Chong EA; Svoboda J; Wohlfarth P; Nasta SD; Williamson S; Landsburg JD; Gerson JN; Barta SK; Pajarillo R; Myers J; Chen AI; Schachter L; Yelton R; Ballard HJ; Hodges Dwinal A; Gier S; Victoriano D; Weber E; Napier E; Garfall A; Porter DL; Jäger U; Maziarz RT; Ruella M; Schuster SJ
Ann Oncol; 2022 Sep; 33(9):916-928. PubMed ID: 35690221
[TBL] [Abstract][Full Text] [Related]
50. Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma.
Mohty R; Moreno Vanegas Y; Chavez JC; Kharfan-Dabaja MA
Expert Rev Anticancer Ther; 2023 Feb; 23(2):121-126. PubMed ID: 36662602
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
[TBL] [Abstract][Full Text] [Related]
52. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.
Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J
Front Oncol; 2021; 11():698607. PubMed ID: 34381720
[TBL] [Abstract][Full Text] [Related]
54. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
[TBL] [Abstract][Full Text] [Related]
55. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
Galletta TJ; Rubinstein JD; Krupski C; Nelson AS; Khoury R; Dandoy CE; Davies SM; Phillips CL
Pediatr Blood Cancer; 2023 May; 70(5):e30271. PubMed ID: 36815392
[TBL] [Abstract][Full Text] [Related]
56. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
57. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
Ahmad A; Uddin S; Steinhoff M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
[TBL] [Abstract][Full Text] [Related]
58. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR; Dickinson M; Purtill D; Barba P; Santoro A; Hamad N; Kato K; Sureda A; Greil R; Thieblemont C; Morschhauser F; Janz M; Flinn I; Rabitsch W; Kwong YL; Kersten MJ; Minnema MC; Holte H; Chan EHL; Martinez-Lopez J; Müller AMS; Maziarz RT; McGuirk JP; Bachy E; Le Gouill S; Dreyling M; Harigae H; Bond D; Andreadis C; McSweeney P; Kharfan-Dabaja M; Newsome S; Degtyarev E; Awasthi R; Del Corral C; Andreola G; Masood A; Schuster SJ; Jäger U; Borchmann P; Westin JR
N Engl J Med; 2022 Feb; 386(7):629-639. PubMed ID: 34904798
[TBL] [Abstract][Full Text] [Related]
59. Advanced Practice Nursing and CAR-T Cell Therapy: Opportunities, Challenges and Future Directions.
Kisielewski D; Naegele M
Semin Oncol Nurs; 2024 Jun; 40(3):151628. PubMed ID: 38594105
[TBL] [Abstract][Full Text] [Related]
60. CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis.
Masucci L; Tian F; Tully S; Feng Z; McFarlane T; Chan KKW; Wong WWL
Med Decis Making; 2024 Apr; 44(3):296-306. PubMed ID: 38486447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]